Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET
Company Participants
Matt Scalo – SVP, IR
Sam Raha – President & CEO
Scott Leffler – CFO
Mark Verratti – COO
Conference Call Participants
Doug Schenkel – Wolfe Research
Puneet Souda – Leerink Partners
David Westenberg – Piper Sandler
Tejas Sawant – Morgan Stanley
Sung Ji Nam – Scotiabank
Andrew Cooper – Raymond James
Tycho Peterson – Jefferies
Lu Li – UBS
Operator
Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Matt Scalo, Senior Vice President of Investor Relations. Please go ahead.
Matt Scalo
Good afternoon, and welcome to the Myriad Genetics First Quarter 2025 Earnings Call. During the call, we will review the financial results we released today and afterwards, we will host a Q&A session. Our quarterly earnings release was issued this afternoon on Form-8K and can be found on our website at investor.myriad.com. I’m Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer, Scott Leffler, our Chief Financial Officer and Mark Verratti, our Chief Operating Officer.
This call can be heard live via webcast at investor.myriad.com and a recording will be archived in our Investors section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward looking statements regarding future events or the future financial performance of the company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with
Read the full article here